Batrash, Firas
Kutmah, Mahmoud
Zhang, Jun
Article History
Received: 22 August 2023
Accepted: 2 October 2023
First Online: 4 November 2023
Declarations
:
: Not applicable.
: FB and MK: None. JZ: Funding: University of Kansas Pilot Project Grant for Cancer Research. Grants/Contracts (past 36 months)—Abbvie, AstraZeneca, BeiGene, Biodesix, Genentech, Hengrui Therapeutics, Janssen, Kahr Medical, Merck, Mirati Therapeutics, Nilogen, Novartis. Consulting fees—AstraZeneca, Bayer, Biodesix, BMS, Cardinal Health, Daiichi Sankyo, Eli Lilly, Hengrui Therapeutics, Mirati Therapeutics, Nexus Health, Novartis, Novocure, Regeneron, Sanofi, Takeda Oncology. Payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events—AstraZeneca, MJH Life Sciences, Novartis, Regeneron, Sanofi. Participation on advisory board—AstraZeneca, Hengrui Therapeutics, Regeneron. Receipt of equipment, materials, drugs, other services—Mirati Therapeutics, Novartis.